Soleno Therapeutics (NASDAQ:SLNO) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Soleno Therapeutics (NASDAQ:SLNO) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $2.91 EPS.

Several other analysts also recently issued reports on SLNO. Wells Fargo & Company initiated coverage on shares of Soleno Therapeutics in a report on Wednesday, August 20th. They set an “overweight” rating and a $123.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Oppenheimer upped their price objective on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Wall Street Zen raised shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. Finally, Guggenheim reaffirmed a “buy” rating and set a $106.00 price objective on shares of Soleno Therapeutics in a report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to data from MarketBeat, Soleno Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $115.09.

Soleno Therapeutics Stock Performance

Shares of SLNO opened at $53.62 on Wednesday. The company’s fifty day moving average is $77.05 and its 200-day moving average is $71.64. Soleno Therapeutics has a 12 month low of $41.50 and a 12 month high of $90.32. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of -12.95 and a beta of -2.72. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.44. The business had revenue of $32.66 million for the quarter, compared to analyst estimates of $3.91 million. Equities analysts expect that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Insider Activity at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the transaction, the insider directly owned 13,206 shares of the company’s stock, valued at approximately $1,092,928.56. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Soleno Therapeutics by 58.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 4,392,696 shares of the company’s stock worth $313,858,000 after acquiring an additional 1,616,720 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Soleno Therapeutics by 47.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,400,418 shares of the company’s stock worth $171,510,000 after purchasing an additional 769,700 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Soleno Therapeutics by 18.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after purchasing an additional 218,511 shares in the last quarter. State Street Corp increased its position in shares of Soleno Therapeutics by 20.2% during the 2nd quarter. State Street Corp now owns 1,404,983 shares of the company’s stock worth $117,709,000 after purchasing an additional 235,784 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Soleno Therapeutics by 47.2% during the 4th quarter. Vestal Point Capital LP now owns 1,060,000 shares of the company’s stock worth $47,647,000 after purchasing an additional 340,000 shares in the last quarter. 97.42% of the stock is owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.